Danish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

lung neoplasms/diarré

Linket gemmes på udklipsholderen
Side 1 fra 1374 resultater
OBJECTIVE Kampo medicine Hangeshashin-to (TJ-14) which contains baicalin, a beta-glucuronidase inhibitor, alleviates diarrhea induced by irinotecan (CPT-11). We conducted a randomized comparative trial to investigate whether support with TJ-14 would prevent and control CPT-11-induced
Purpose: We designed the study to illustrate the OR of programmed cell death-1 (PD-1) or ligand 1 (PD-L1) inhibitor-related diarrhea in patients with non-small cell lung cancer. Method: This systematic review and meta-analysis were put into practice according to the Preferred Reporting

[Chronic diarrhea as a first manifestation of small cell lung cancer. A case report].

Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
We report the case of a 57-year-old man presenting with chronic diarrhea for more than three months and a solitary pulmonary nodule of the right upper lobe. After atypical resection, showing a clinical stage I small cell lung cancer (SCLC), a lobectomy combined with a systematic mediastinal

[Kampo medicines for the prevention of irinotecan-induced diarrhea in advanced non-small cell lung cancer].

Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
A combination of irinotecan hydrochloride (CPT-11; 160 mg/m2, intravenous infusion, day 1) and cisplatin (5-day continuous intravenous infusion; 20 mg/m2/day) was administrated to advanced non-small cell lung cancer patients. They were given Hangeshashin-to (TJ-14), a Kampo medicine, to prevent the
UNASSIGNED Diarrhea and oral mucositis induced by afatinib can cause devastating quality of life issues for patients undergoing afatinib treatment. Several studies have shown that hangeshashin-to (TJ-14) might be useful for chemotherapy-induced diarrhea and oral mucositis. In this study, we

Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea.

Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Previous studies showed that some patients after the treatment of anti-programmed cell death protein-1 (anti-PD-1) antibodies experienced immune-related diarrhea. In this study, we aim to explore the association between intestinal microbiota and immune-related
Diarrhea is a common adverse reaction in patients with cancer receiving chemotherapy, for which there is currently no effective method of treatment. Shengjiang Xiexin decoction (SXD), a classic traditional Chinese medicine (TCM) formula, has shown efficacy in alleviating
Camptothecin possesses broad antitumor spectra on various cancers. In spite of its marked tumor suppressing potency, camptothecin is too hydrophobic to be solved in water, and therefore it is not currently in clinical use. CPT-11 (irinotecan) is one of the hydrophilic analogs of camptothecin and
Afatinib is an effective therapy for metastatic non-small cell lung cancer (NSCLC) but it is associated with a relatively high incidence of severe diarrhea. The association between pre-treatment candidate predictors (age, sex, race, performance status, renal function, hemoglobin, and measures of
BACKGROUND Irinotecan (CPT-11) can be used as a first-line therapeutic drug against extensive-stage small cell lung cancer (SCLC); it can also be used in second-line treatment for SCLC. CPT-11-induced delayed diarrhea restricts its clinical application. This study aimed to confirm whether Banxia

Clonidine and lidamidine to inhibit watery diarrhea in a patient with lung cancer.

Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
A patient with watery diarrhea syndrome secondary to bronchogenic carcinoma responded to treatment with clonidine and lidamidine. Stool weight decreased to 43% and 53% of control on two separate trials of clonidine. Stool weight decreased to 35% of control during a trial of lidamidine. Both
Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available with manageable safety profile, approved worldwide for the treatment of several neoplasms, including lung, breast, kidney and pancreatic cancer as well as gastro-intestinal stromal tumours and chronic
BACKGROUND We describe 16 months' single-institution experience with gefitinib ("Iressa", ZD1839) used as "ultimum refugium" for pretreated non-small-cell lung cancer (NSCLC) patients. METHODS Toxicity, response and survival data of NSCLC patients participating in a compassionate-use program with
Recently, targeted agents were reported to improve overall survival, progression-free survival (PFS), response rate, and quality of life compared with cytotoxic chemotherapies, which provides hope for the treatment of non-small-cell lung cancer (NSCLC). The network meta-analysis is applied to
Deltag i vores
facebook-side

Den mest komplette database med medicinske urter understøttet af videnskab

  • Arbejder på 55 sprog
  • Urtekurer, der understøttes af videnskab
  • Urtegenkendelse ved billede
  • Interaktivt GPS-kort - tag urter på stedet (kommer snart)
  • Læs videnskabelige publikationer relateret til din søgning
  • Søg medicinske urter efter deres virkninger
  • Organiser dine interesser og hold dig opdateret med nyhedsundersøgelser, kliniske forsøg og patenter

Skriv et symptom eller en sygdom, og læs om urter, der kan hjælpe, skriv en urt og se sygdomme og symptomer, den bruges mod.
* Al information er baseret på offentliggjort videnskabelig forskning

Google Play badgeApp Store badge